JP2019515033A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515033A5 JP2019515033A5 JP2019507069A JP2019507069A JP2019515033A5 JP 2019515033 A5 JP2019515033 A5 JP 2019515033A5 JP 2019507069 A JP2019507069 A JP 2019507069A JP 2019507069 A JP2019507069 A JP 2019507069A JP 2019515033 A5 JP2019515033 A5 JP 2019515033A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- day
- composition according
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 16
- 150000002148 esters Chemical class 0.000 claims description 6
- 239000000651 prodrug Substances 0.000 claims description 6
- 229940002612 prodrug Drugs 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims description 2
- 208000010796 X-linked adrenoleukodystrophy Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326436P | 2016-04-22 | 2016-04-22 | |
| US62/326,436 | 2016-04-22 | ||
| PCT/US2017/029120 WO2017185087A1 (en) | 2016-04-22 | 2017-04-24 | Use of thyroid beta-agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515033A JP2019515033A (ja) | 2019-06-06 |
| JP2019515033A5 true JP2019515033A5 (https=) | 2020-06-11 |
| JP6931042B2 JP6931042B2 (ja) | 2021-09-01 |
Family
ID=60116400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019507069A Active JP6931042B2 (ja) | 2016-04-22 | 2017-04-24 | 甲状腺ベータアゴニストの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11351183B2 (https=) |
| EP (1) | EP3445373B1 (https=) |
| JP (1) | JP6931042B2 (https=) |
| KR (1) | KR102407059B1 (https=) |
| AU (1) | AU2017252126B2 (https=) |
| BR (1) | BR112018071586A2 (https=) |
| CA (1) | CA3021681C (https=) |
| ES (1) | ES2992773T3 (https=) |
| MX (1) | MX385085B (https=) |
| WO (1) | WO2017185087A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3445373B1 (en) | 2016-04-22 | 2024-08-21 | Viking Therapeutics, Inc. | Use of thyroid beta-agonists |
| ES3053674T3 (en) | 2018-03-22 | 2026-01-23 | Viking Therapeutics Inc | Crystalline forms and methods of producing crystalline forms of a compound |
| WO2020117962A1 (en) | 2018-12-05 | 2020-06-11 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| US11752161B2 (en) | 2020-03-27 | 2023-09-12 | Gannex Pharma Co., Ltd. | Pharmaceutical compositions, method of making and method of using thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| CA2543132A1 (en) | 2003-10-23 | 2005-05-19 | Celgene Corporation | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| CN1882327A (zh) | 2003-11-19 | 2006-12-20 | 症变治疗公司 | 含磷的新的拟甲状腺素药 |
| WO2006128058A2 (en) | 2005-05-26 | 2006-11-30 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
| CA2638753A1 (en) | 2004-12-08 | 2006-06-15 | Sirion Therapeutics, Inc. | Methods, assays and compositions for treating retinol-related diseases |
| WO2006128056A2 (en) * | 2005-05-26 | 2006-11-30 | Metabasis Therapeutics, Inc. | Novel phosphinic acid-containing thyromimetics |
| EP1987827A1 (en) | 2006-02-20 | 2008-11-05 | Takeda Pharmaceutical Company Limited | Novel pharmaceutical |
| US20110071208A1 (en) | 2009-06-05 | 2011-03-24 | Protiva Biotherapeutics, Inc. | Lipid encapsulated dicer-substrate interfering rna |
| WO2011038207A1 (en) * | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
| CN103649103A (zh) | 2011-06-21 | 2014-03-19 | 阿尔尼拉姆医药品有限公司 | 用于抑制载脂蛋白c-iii(apoc3)基因表达的组合物与方法 |
| WO2014178892A1 (en) | 2013-05-03 | 2014-11-06 | Scanlan Thomas S | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
| EP3259246B1 (en) | 2015-02-20 | 2023-03-22 | Oregon Health & Science University | Derivatives of sobetirome |
| EP3423379B1 (en) | 2016-02-29 | 2020-04-01 | Philip Morris Products S.a.s. | Hinge-lid container and blank |
| EP3445373B1 (en) | 2016-04-22 | 2024-08-21 | Viking Therapeutics, Inc. | Use of thyroid beta-agonists |
| CA3021677C (en) | 2016-04-22 | 2024-11-12 | Viking Therapeutics, Inc. | USE OF BETA-AGONISTS OF THYROID HORMONES |
| CN109475121B (zh) | 2016-05-18 | 2021-06-25 | 俄勒冈健康科学大学 | 苏比替罗衍生物 |
-
2017
- 2017-04-24 EP EP17786798.3A patent/EP3445373B1/en active Active
- 2017-04-24 MX MX2018012900A patent/MX385085B/es unknown
- 2017-04-24 WO PCT/US2017/029120 patent/WO2017185087A1/en not_active Ceased
- 2017-04-24 US US16/095,228 patent/US11351183B2/en active Active
- 2017-04-24 AU AU2017252126A patent/AU2017252126B2/en active Active
- 2017-04-24 ES ES17786798T patent/ES2992773T3/es active Active
- 2017-04-24 KR KR1020187033713A patent/KR102407059B1/ko active Active
- 2017-04-24 BR BR112018071586-7A patent/BR112018071586A2/pt not_active Application Discontinuation
- 2017-04-24 CA CA3021681A patent/CA3021681C/en active Active
- 2017-04-24 JP JP2019507069A patent/JP6931042B2/ja active Active
-
2022
- 2022-05-06 US US17/738,621 patent/US11951114B2/en active Active
-
2024
- 2024-03-05 US US18/595,919 patent/US12440502B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020097577A5 (https=) | ||
| JP2017518334A5 (https=) | ||
| JP2018534348A5 (https=) | ||
| JP2015078230A5 (https=) | ||
| JP2018111728A5 (https=) | ||
| RU2018114447A (ru) | Введение дейтерированных усилителей cftr | |
| JP2017513836A5 (https=) | ||
| CN109415406A (zh) | 羊毛甾醇前药化合物及其制备方法和应用 | |
| JP2016515561A5 (https=) | ||
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| JP2018531941A5 (https=) | ||
| JP2019515033A5 (https=) | ||
| JP2015155440A5 (https=) | ||
| JP2017505285A5 (https=) | ||
| CN108026053A8 (zh) | 作为mIDH1抑制剂的稠合的咪唑类化合物 | |
| JP2018530578A5 (https=) | ||
| JP2019516739A5 (https=) | ||
| JP2014218522A5 (https=) | ||
| JP2016534081A5 (ja) | ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法 | |
| JP2017508817A5 (https=) | ||
| JP2017502074A5 (https=) | ||
| JP2018521056A5 (https=) | ||
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| JP2018524306A5 (https=) | ||
| EA201791138A1 (ru) | Фармацевтическая композиция, ее приготовление и применения |